Indeed, improving the overall survival of LC patients is the real challenge; targeting TGF-β, particularly in combination with chemo- and immunotherapy, will thus represent a starting point for future improvements to LC management, in the attempt to better overcome this difficult-to-treat tumor. This evidence concerns the gene TGFB1 and neoplasm.